Abstract: The invention relates to an isolated anti-vascular endothelial growth factor-C (VEGFC) antibody or a functional fragment thereof, said antibody comprising a heavy chain comprising at least one, preferentially at least two, preferentially three, of CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N° 6, 7 and 8 and a light chain comprising at least one, preferentially at least two, preferentially three of CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N° 9, 10 and 11, respectively.

Abstract: Renal Cell Carcinoma (RCC) encompasses a heterogeneous group of cancers derived from renal tubular epithelial cells and has a worldwide mortality. However, mortality rates have barely improved over the last 20 years. Novel biomarkers and biomarkers are thus urgently required for this cancer. The inventors have devised a strategy to produce mouse cancer cell lines of progressively enhanced aggressiveness and specialization. The mouse renal cancer cell line RENCA was serially passaged in vivo using multiple implantation strategies designed to replicate different aspects of primary tumour growth and metastasis. Transcriptomic and epigenomic data has been acquired for the derived cell lines and primary analyses have been performed. The inventors then selected plurality of genes with no reported role in RCC which were upregulated in their specialized cell lines, and checked their relevance in patient data and clinical samples.

Abstract: The present invention relates to a compound or a pharmaceutically acceptable salt thereof of formulae (I) and (II), and a pharmaceutical composition comprising such compound for use for treating a cancer, particularly a cancer overexpressing CXCR1 and CXCR2 receptors, such as medulloblastoma, head and neck and kidney cancer. The invention further relates to such compounds for use for treating macular degeneration.

Abstract: The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a cancer, in particular renal cell carcinoma (RCC) to sunitinib, to a method of selecting an appropriate treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to corresponding kits.

Abstract: The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a tumor, in particular renal cell carcinoma (RCC) to a cancer treatment, to a method of selecting an appropriate treatment of cancer, to a method of screening or identifying a compound suitable for improving the treatment of a cancer, and to corresponding kits.

Abstract: The invention provides an isolated antibody or a fragment thereof, which is directed to the human chemokines CXCL1, CXCL7 and CXCL8, said antibody or fragment being capable of binding to the human chemokine CXCL1 with an equilibrium dissociation constant (KD) of at most 16 nM, to the human chemokine CXCL7 with an equilibrium dissociation constant (KD) of at most 5 nM and to the human chemokine CXCL8 with an equilibrium dissociation constant (KD) of at most 45 nM, as determined by surface plasmon resonance. The invention also provides some applications of said isolated antibody.

Abstract: An in vitro method for predicting a likelihood of an individual having a cancer to efficiently respond to an anti-cancer treatment, said method including the steps: of a) measuring the level of nuclear expression of TRF2 in a biopsy obtained from said individual, b) comparing the level obtained in step a) to a reference value, and c) determining the predicted likelihood of said individual to efficiently respond to said anti-cancer treatment from the comparison performed in step b).

Abstract: The invention relates in particular to an in vitro or ex vivo method for predicting the response of a patient to treatment with at least one HER2-blocking agent, said method including the steps of: i) identifying the nucleotide at the rs3746083 polymorphic site, for at least one allele, in particular the two alleles of the gene coding the tristetraprolin protein, in a biological sample from said patient; and/or ii) determining the concentration of the tristetraprolin protein in a biological sample from said patient, wherein said patient is suffering from HER2-positive cancer.

Abstract: The invention provides an isolated antibody or a fragment thereof, which is directed to the human chemokines CXCL1, CXCL7 and CXCL8, said antibody or fragment being capable of binding to the human chemokine CXCL1 with an equilibrium dissociation constant (KD) of at most 16 nM, to the human chemokine CXCL7 with an equilibrium dissociation constant (KD) of at most 5 nM and to the human chemokine CXCL8 with an equilibrium dissociation constant (KD) of at most 45 nM, as determined by surface plasmon resonance. The invention also provides some applications of said isolated antibody.

Abstract: The invention relates in particular to an in vitro or ex vivo method for predicting the response of a patient to treatment with at least one HER2-blocking agent, said method including the steps of: i) identifying the nucleotide at the rs3746083 polymorphic site, for at least one allele, in particular the two alleles of the gene coding the tristetraprolin protein, in a biological sample from said patient; and/or ii) determining the concentration of the tristetraprolin protein in a biological sample from said patient, wherein said patient is suffering from HER2-positive cancer.